Earnings Recap — Q2 FY2026
CY Q3 2026 · Reported July 30, 2026 · Beat 7 of last 7 quarters
The Buildout is a website built on agentic AI tools, currently in beta, and could have factual errors.
Mettler-Toledo's strong quarter, particularly in China and emerging markets, signals continued investment in laboratory and industrial automation, digitalization, and onshoring—key drivers of the AI infrastructure buildout. The company's exposure to biopharma, semiconductor, and battery end markets positions it to benefit from capacity expansion and reshoring trends, which are integral to the buildout of advanced manufacturing and data-driven processes.
Q2 sales were $1.0 billion, up 7% in USD and 6% in local currency, with organic growth of 4%. Adjusted EPS of $11.46 beat consensus by $0.68, up 14% YoY. Organic growth was led by Asia/RoW (+9%, including China +9%), Europe +4%, and Americas +1%. By segment, Lab grew 4%, Industrial 3% (Core Industrial +4%, Product Inspection +1%), Food Retail +11%, and Service +7% organically. Adjusted operating margin expanded 50 bps to 29.3%. The quarter included a $52 million gross IEEPA tariff refund benefit, partially offset by a $28 million refund to customers, both excluded from adjusted results.
Management raised full-year 2026 local currency sales growth guidance to approximately 4% to 5% (from ~4%), with organic growth of 3% to 4%. Adjusted EPS guidance was raised to $47.15–$47.50, representing 10%–11% growth (11%–12% ex-currency), up from prior 8%–10%. For Q3, they expect local currency sales growth of ~4% and adjusted EPS of $12.00–$12.15. The tone was cautiously optimistic, citing improved market conditions, especially in China and emerging markets, and strong momentum in automation, digitalization, and onshoring. They acknowledged geopolitical volatility (Middle East) but have not included an escalation in guidance. Management raised share repurchases to $875 million for the full year.
“We are encouraged by our Q2 results and improved market conditions, especially in China and emerging markets.”
on Market conditions
“We see some good activities, some RFQs here related to reshoring, but I still would say it's early innings. I think this momentum will continue to pick up in the second half and also as we go into 2027.”
on Onshoring/reshoring
“We are extremely well positioned for that because about 50% of our sales go into production, plus about 20% QA/QC, where we cover a lot of the value chain there.”
on Biopharma positioning
Can you dive into the acceleration in China? What does the momentum look like when it comes to pharma versus non-pharma and the consistency you expect in coming quarters?
China grew 9% in Q2, led by Industrial with double-digit growth, benefiting from biopharma, food, and hot segments like battery. Lab growth was more modest but expected to improve in H2, with some indications of additional academia funding. For H2, we expect high single-digit growth in China for Q3 and the full year.
Can you unpack the underlying assumptions by end market and segment for the back half of the year?
For Q3, Lab mid-single digit, Core Industrial low single digit (lapping a 10% comp), Product Inspection mid-single digit, Retail flat. Americas low to mid-single digit (lapping 9% comp), Europe low single digit, China high single digit. For the full year, Lab low to mid-single, Core Industrial low to mid-single, PI high single, Retail low to mid-single.
How are margins tracking versus your plan? Any updated view on full-year margin expectation?
We feel very good about execution. Q2 operating margin was up 100 bps ex-currency. For the full year, we expect operating margin up 60–70 bps ex-currency, modestly better than prior. On a reported basis, up 10–20 bps. Tariff refunds are excluded from adjusted results and guidance.